Vaxart (OTCMKTS:VXRT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• Vaxart reported quarterly EPS of $(0.06), beating the consensus estimate of $(0.12) by $0.06. The company reported a 14.51% net margin and 61.43% return on equity.
• Shares fell $0.02 to $0.57, with a market capitalization of approximately $138.4 million. The stock has traded between $0.30 and $0.84 over the past year.
• Institutional ownership stands at 18.05%, with several investors increasing their stakes. Wall Street’s consensus rating remains “Hold”, following a Zacks Research upgrade.

Vaxart (OTCMKTS:VXRT - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06, Zacks reports. Vaxart had a net margin of 14.51% and a return on equity of 61.43%.

Vaxart Price Performance

Shares of OTCMKTS:VXRT traded down $0.02 on Thursday, hitting $0.57. 181,566 shares of the company's stock were exchanged, compared to its average volume of 557,097. The stock has a market capitalization of $138.42 million, a price-to-earnings ratio of 3.80 and a beta of 1.10. Vaxart has a 12 month low of $0.30 and a 12 month high of $0.84. The business's 50 day simple moving average is $0.56 and its two-hundred day simple moving average is $0.63.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. increased its position in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock valued at $107,000 after purchasing an additional 34,075 shares during the period. Invesco Ltd. raised its holdings in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 70,568 shares in the last quarter. Creative Planning purchased a new stake in shares of Vaxart in the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart in the 1st quarter worth approximately $31,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after purchasing an additional 478,111 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Vaxart to a "hold" rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Vaxart currently has an average rating of "Hold".

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source